TNXP - DBV Technologies' Positive Data And Other News: The Good Bad And Ugly Of Biopharma
DBV Technologies Reports Positive Extension Study Results
DBV Technologies (DBVT) reported positive results from its open label extension of the Phase 3 study. The data showed that the participants underwent sustained clinical benefit with an extra two years of treatment with Viaskin Peanut. The Phase III PEPITES study aimed to assess the implications of Viaskin Peanut in children with peanut allergy.
The three years long extension study PEOPLE showed than Viaskin Peanut or DBV712 was linked to sustained response over a three-year treatment period. 75.9 percent of the patients reported improvement in eliciting dose ((ED))